Table 4.
Multivariate regression analysis of the impact of GnRH antagonist type.
| Before PSM | After PSM | |||||
|---|---|---|---|---|---|---|
| Coefficient | t | P | Coefficient | t | P | |
| OPU number | -0.002 | -0.126 | 0.900 | -0.002 | -0.105 | 0.917 |
| Number of usable embryos | 0.008 | 0.429 | 0.668 | 0.033 | 1.412 | 0.158 |
| Number of good quality embryos | 0.018 | 0.942 | 0.346 | 0.038 | 1.566 | 0.117 |
| Wald value | 95% CI | P | Wald value | 95% CI | P | |
| OHSS | 1.181 | 0.211, 1.561 | 0.277 | 3.309 | 0.958, 3.174 | 0.069 |
| Clinical pregnancy | 0.363 | 0.729, 1.182 | 0.547 | 1.252 | 0.647, 1.126 | 0.263 |
| Live birth | 0.001 | 0.787, 1.279 | 0.980 | 0.321 | 0.697, 1.220 | 0.571 |
| Multiple pregnancy | 3.642 | 0.987, 2.732 | 0.056 | 2.134 | 0.853, 2.967 | 0.144 |
| Miscarriage | 0.182 | 0.542, 1.481 | 0.669 | 0.402 | 0.443, 1.515 | 0.526 |
PSM, propensity score matching; OPU, oocytes pick up; OHSS, ovarian hyper-stimulation syndrome; 95% CI, 95% confidential interval.